Overview

A Dose Escalation Study of APR003 in Patients With Advanced Colorectal Cancer (CRC) With Malignant Liver Lesions

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

A Phase 1 dose escalation study to evaluate APR003 in patients with advanced colorectal cancer (CRC) with malignant liver lesions

Phase:

Phase 1

Details

Lead Sponsor:

Apros Therapeutics, Inc